Dashboard
Manage Tickers

DTIL PRECISION BIOSCIENCES INC

Nasdaq precisionbiosciences.com


$ 6.55 $ -0.67 (-9.1 %)    

Tuesday, 04-Nov-2025 17:59:04 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 6.69
$ 7.25
$ 6.55 x 173
$ 7.77 x 7
$ 6.56 - $ 7.45
$ 3.61 - $ 8.82
107,382
na
88.69M
$ 1.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-03-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-26-2025 12-31-2024 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-27-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-04-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-09-2022 03-31-2022 10-Q
16 03-15-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-18-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 08-13-2020 06-30-2020 10-Q
23 05-15-2020 03-31-2020 10-Q
24 03-10-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 04-29-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

precision-biosciences-q3-eps-184-misses-134-estimate-sales-13000k-miss-5400m-estimate
Precision BioSciences Q3 EPS $(1.84) Misse...
11/03/2025 12:01:52

Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(1.84) per share which missed the analyst consensus estimate ...

earnings-scheduled-for-november-3-2025
Earnings Scheduled For November 3, 2025
11/03/2025 11:11:31

precision-biosciences-to-present-new-pbgene-hbv-phase-1-data-showing-safety-and-antiviral-activity-at-aasld-liver-meeting-2025-on-nov-10-in-washington-dc
Precision BioSciences To Present New PBGEN...
10/14/2025 11:08:15

precision-biosciences-announced-the-publication-demonstrating-a-wide-variety-of-gene-edits-using-arcus-nucleases-to-stimulate-a-homology-dependent-repair-mechanism
Precision Biosciences Announced The Public...
10/09/2025 11:20:26

Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene ins...

precision-biosciences-opens-first-us-eliminate-b-site-at-massachusetts-general-hospital-actively-recruiting-chronic-hepatitis-b-patients
Precision BioSciences Opens First U.S. ELI...
10/07/2025 11:16:03

Massachusetts General Hospital, Harvard Medical School, actively recruiting chronic hepatitis B patients along with multiple gl...

iecure-to-present-otc-hope-clinical-trial-data-of-ecur-506-in-ornithine-transcarbamylase-deficiency
iECURE To Present OTC-HOPE Clinical Trial ...
10/02/2025 12:08:02

precision-biosciences-announces-late-breaking-poster-presentation-at-wms-2025-to-highlight-latest-long-term-preclinical-efficacy-and-durability-data-supporting-pbgene-dmd-for-duchenne-muscular-dystrophy-treatment
Precision BioSciences Announces Late-Break...
09/30/2025 11:06:08

- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchen...

precision-biosciences-presents-clinical-data-from-phase-1-eliminate-b-trial-of-pbgene-hbv-in-patients-with-chronic-hepatitis-b-at-ice-hbv
Precision BioSciences Presents Clinical Da...
09/12/2025 11:02:42

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platfor...

precision-biosciences-to-be-issued-us-patent-for-pbgene-hbvarcus-nuclease-utilized-in-the-companys-lead-in-vivo-gene-editing-program-the-us-patent-will-have-an-expiration-date-in-march-2042
Precision Biosciences To Be Issued Us Pate...
09/08/2025 11:10:39

Strengthens the Company's intellectual property portfolio for lead in vivo program PBGENE-HBV with U.S. patent protection i...

iecure-announces-it-will-present-additional-data-from-its-ongoing-otc-hope-clinical-trial-of-ecur-506-for-neonatal-onset-ornithine-transcarbamylase-deficiency-at-two-upcoming-conferences-in-kyoto-japan
iECURE Announces It Will Present Additiona...
08/25/2025 12:09:22

iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies...

precision-biosciences-q2-eps-213-misses-157-estimate-sales-1800k-miss-627m-estimate
Precision BioSciences Q2 EPS $(2.13) Misse...
08/07/2025 11:03:33

Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

precision-biosciences-announces-phase-1-eliminate-b-cohort-1-safety-and-efficacy-at-02-mgkg-with-4769-hbsag-reduction-durable-50-response-at-7-months-sulkowski-named-head-clinical-development-advisor-and-cash-runway-extended-to-h2-2027
Precision BioSciences Announces Phase 1 EL...
08/06/2025 11:16:50

precision-biosciences-says-fda-grants-orphan-drug-designation-for-pbgene-dmd-for-treatment-of-duchenne-muscular-dystrophy
Precision BioSciences Says FDA Grants Orph...
07/23/2025 11:03:09

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platfor...

precision-biosciences-gets-fda-orphan-drug-designation-for-pbgene-dmd-for-treatment-of-duchenne-muscular-dystrophy
Precision BioSciences Gets FDA Orphan Drug...
07/17/2025 15:52:11

https://t.co/eGDeZfYDhp

precision-biosciences-announced-dditional-preclinical-data-for-pbgene-dmd-in-vivo-gene-editing-approach-for-duchenne-muscular-dystrophy-dmd-clinical-trial-application-submission-expected-in-2025-with-clinical-data-expected-in-2026
Precision Biosciences Announced dditional ...
07/16/2025 11:05:24

New preclinical data for the PBGENE-DMD final clinical candidate demonstrates an increase in dystrophin positive muscle cells a...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/25/2025 12:09:37

Core News & Articles
Market-Moving News for June 25th
06/25/2025 11:17:32

QS: 42% | QuantumScape Achieves Key 2025 Milestone In The Scale-Up Of Its Production Capabilities With The Successful Integrati...

precision-biosciences-receives-fda-rare-pediatric-disease-designation-for-pbgene-dmd-in-the-treatment-oo-duchenne-muscular-dystrophy
Precision BioSciences Receives FDA Rare Pe...
06/25/2025 11:02:14

hc-wainwright--co-reiterates-buy-on-precision-biosciences-maintains-60-price-target
HC Wainwright & Co. Reiterates Buy on Prec...
05/21/2025 10:56:30

HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION